FATE THERAPEUTICS INC's ticker is FATE and the CUSIP is 31189P102. A total of 37 filers reported holding FATE THERAPEUTICS INC in Q4 2016. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2016 | $768,000 | +76.1% | 246,126 | -4.0% | 0.07% | +34.0% |
| Q2 2016 | $436,000 | -2.9% | 256,426 | +2.8% | 0.05% | -13.1% |
| Q1 2016 | $449,000 | -62.0% | 249,374 | -28.8% | 0.06% | -47.0% |
| Q4 2015 | $1,181,000 | -30.1% | 350,306 | +10.5% | 0.12% | -22.3% |
| Q3 2015 | $1,690,000 | -14.5% | 317,088 | +3.8% | 0.15% | +5.7% |
| Q2 2015 | $1,976,000 | – | 305,481 | – | 0.14% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Polaris Venture Management Co. V, L.L.C. | 569,889 | $46,987,000 | 60.92% |
| Johnson & Johnson Innovation - JJDC, Inc. | 3,379,064 | $278,604,000 | 36.08% |
| Darwin Global Management, Ltd. | 1,370,133 | $112,967,000 | 22.12% |
| Redmile Group, LLC | 12,957,222 | $1,068,323,000 | 15.05% |
| Copernicus Capital Management, LLC | 8,000 | $660,000 | 10.66% |
| Casdin Capital, LLC | 3,400,000 | $280,330,000 | 8.35% |
| Grosvenor Holdings, L.L.C. | 1,123,576 | $92,639,000 | 6.81% |
| DAFNA Capital Management LLC | 314,360 | $25,919,000 | 6.15% |
| Ally Bridge Group (NY) LLC | 270,000 | $22,262,000 | 4.27% |
| Ghost Tree Capital, LLC | 185,000 | $15,253,000 | 3.58% |